Publications by authors named "Rita Marchi Cappelletti"
Article Synopsis
- Emicizumab is a bispecific antibody used to treat hemophilia A, but typical coagulation tests can't accurately measure its effects due to over-correction.
- This study involved six adult patients receiving emicizumab, where their treatment response was monitored through thrombin generation (TG) and fibrin clot formation (FCF) over several weeks.
- Results indicated that TG and FCF improved significantly with treatment, suggesting that these global coagulation assays could serve as valuable indicators of emicizumab's effectiveness and contribute to more personalized treatment plans.
Individuals with hypertension, dyslipidemia or diabetes are at a higher risk to suffer cardiovascular disease than other people; while impaired fibrin structure/function may contribute to further raise the cardiovascular risk in the former. The purpose of this work was to study the fibrin network and fibrin degradation properties in hypertensive (HT) patients, pharmacologically treated, 124 +/- 11 mmHg, systolic blood pressure, and 70 +/- 10 mmHg, diastolic blood pressure, n = 12; metabolic dyslipidemic patients (DL), cholesterol: 5.7 +/- 1.
View Article and Find Full Text PDF